The loss of orexin neurons and orexin release in MS may be relevant to this, with preclinical data showing that orexin-A inhibition decreases serotonin neurons across different brain regions [131], indicating that the lower orexin-A levels in MS will decrease serotonin availability for the melatonergic pathway. This evidence concerns the gene HCRT and myeloid sarcoma.